Overview

Dapagliflozin on Volume Vascular Outcomes.

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

The purpose of the DAPA-VOLVO trial is to investigate the effects of Dapagliflozin on top of recommended standard therapy on volume status and vascular function in clinically stable heart failure patients after hospitalization because of an acute decompensated heart failure event.

Phase:

Phase 4

Details

Lead Sponsor:

Frank Ruschitzka

Collaborator:

AstraZeneca

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin